Atara Biotherapeutics Inc

NASDAQ:ATRA  
13.60
+0.71 (+5.51%)
Products

Atara Biotherapeutics Announces Early-Stage Data From Multiple Sclerosis Treatment

Published: 09/11/2020 12:11 GMT
Atara Biotherapeutics Inc (ATRA) - Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients With Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of Ata188.
Atara Biotherapeutics Inc - Patients Who Achieved Sdi at Any Timepoint Maintained It at All Future Timepoints.
Atara Biotherapeutics Inc - Higher Proportion of Patients Showing Sdi With Increasing Dose.
Atara Biotherapeutics Inc - Patients Achieving Sdi Also Demonstrated Trend Toward Improvement in Fatigue and Physical Function at 12 Months.
Atara Biotherapeutics Inc - First Available Data From Open Label Expansion Show Patients With Sdi at 12 Months, Maintained Sdi at Later Time Points.